Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by VALNEVA SE

News headline image
Valneva Reports Sustained 94% Seroresponse Five Years After a Single Dose of Chikungunya Vaccine IXCHIQ®
From VALNEVA SE
Via GlobeNewswire
News headline image
Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2
From VALNEVA SE
Via GlobeNewswire
News headline image
Valneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026
From VALNEVA SE
Via GlobeNewswire
News headline image
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
From VALNEVA SE
Via GlobeNewswire
News headline image
Valneva Provides Update on IXCHIQ® in the United Kingdom
From VALNEVA SE
Via GlobeNewswire
News headline image
Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
From VALNEVA SE
Via GlobeNewswire
News headline image
Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates
From VALNEVA SE
Via GlobeNewswire
News headline image
Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026
From VALNEVA SE
Via GlobeNewswire
News headline image
Valneva Announces Successful Outcome of its Annual General Meeting
From VALNEVA SE
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.